We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Eli Lilly’s Investigational Checkpoint Inhibitor for NSCLC Rejected Over China-Only Study
Eli Lilly’s Investigational Checkpoint Inhibitor for NSCLC Rejected Over China-Only Study
Because its phase 3 trial was conducted only in China, the FDA has told Eli Lilly to go back to the drawing board with its promising investigational checkpoint inhibitor sintilimab for the treatment of nonsmall-cell lung cancer (NSCLC).